FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

A / - -		00540	
Washington,	D.C.	20549	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Roberts Margo R						2. Issuer Name and Ticker or Trading Symbol Unity Biotechnology, Inc. [UBX]								heck al		,		son(s) to Is:	
(Last)	(Fi	rst) ((Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/23/2023									Officer pelow)	(give title		Other (s below)	specify
C/O UNITY BIOTECHNOLOGY, INC. 285 EAST GRAND AVENUE					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street)	· C	Α 9	94080						-					ı		iled by Mor		n One Repo	
FRANC!	ISCO S				Rul	Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									led to										
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date			Transaction Dispose Code (Instr. 5)		rities Acquired (A) ed Of (D) (Instr. 3, 4		4 and Securiti Benefic		ies For ially (D) Following (I) (n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership		
					Code	v	Amount	t (A) or Pr		_ Tr	Transaction(s) (Instr. 3 and 4)				(Instr. 4)				
		Ta	able II - De (e.						uired, Di s, options						ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate,	Code (Ins		on of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares	1					
Stock Option (Right to Buy)	\$3.25	06/23/2023			A		6,000		(1)	06.	/22/2033	Common Stock	6,000	\$0.	00	6,000		D	

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 23, 2023 or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.

Remarks:

/s/ Alexander Nguyen,

Attorney-in-Fact for Margo R. 06/26/2023

Roberts

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.